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Background: Clinical and imaging surveillance practices following endovascular aneurysm repair (EVAR)
for intact abdominal aortic aneurysm (AAA) vary considerably and compliance with recommended lifelong
surveillance is poor. The aim of this study was to develop a dynamic prognostic model to enable stratifica-
tion of patients at risk of future secondary aortic rupture or the need for intervention to prevent rupture
(rupture-preventing reintervention) to enable the development of personalized surveillance intervals.
Methods: Baseline data and repeat measurements of postoperative aneurysm sac diameter from the
EVAR-1 and EVAR-2 trials were used to develop the model, with external validation in a cohort from
a single-centre vascular database. Longitudinal mixed-effects models were fitted to trajectories of sac
diameter, and model-predicted sac diameter and rate of growth were used in prognostic Cox proportional
hazards models.
Results: Some 785 patients from the EVAR trials were included, of whom155 (19⋅7 per cent) experienced
at least one rupture or required a rupture-preventing reintervention during follow-up. An increased risk
was associated with preoperative AAA size, rate of sac growth and the number of previously detected
complications. A prognostic model using predicted sac growth alone had good discrimination at 2 years
(C-index 0⋅68), 3 years (C-index 0⋅72) and 5 years (C-index 0⋅75) after operation and had excellent external
validation (C-index 0⋅76–0⋅79). More than 5 years after operation, growth rates above 1mm/year had a
sensitivity of over 80 per cent and specificity over 50 per cent in identifying events occurringwithin 2 years.
Conclusion: Secondary sac growth is an important predictor of rupture or rupture-preventing reinter-
vention to enable the development of personalized surveillance intervals. A dynamic prognostic model
has the potential to tailor surveillance by identifying a large proportion of patients who may require less
intensive follow-up.
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Introduction
Endovascular aneurysm repair (EVAR) has become the
primary choice of repair for many patients with an intact
abdominal aortic aneurysm (AAA)1 and is a less invasive
alternative to traditional open repair of AAA. Evidence
from RCTs of EVAR versus open repair has shown that
EVAR has an early mortality benefit; however, this survival
benefit is eroded within a few years after operation2–5,
with significantly higher AAA-related mortality and rates
of secondary rupture2,6. Guidelines7 therefore recommend
lifelong clinical and imaging surveillance after EVAR
in order to detect complications that require timely
reintervention.
Compliance with lifelong surveillance is, however, poor.
Among Medicare beneficiaries in the USA, 50 per cent of
patients were lost to annual imaging follow-up by 5 years8.
Compliance also dropped off in the EVAR-1 trial2, where
only half of the surviving patients in the EVAR group still
underwent annual CT 6 years after randomization. This
loss to follow-up could partly be explained by an ageing
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population (in EVAR-1, over 40 per cent of patients still
alive after 6 years were aged over 80 years). However, there
are also concerns about the frequent use of CT and result-
ing radiation burden that might suggest a less intensive CT
surveillance protocol is required7, with colour duplex ultra-
sonography recommended as a reasonable alternative to
CT9,10. In addition, the costs associated with lifelong CT
surveillance are high; one-third of the total costs of EVAR
follow-up in the first 5 years is associated with yearly post-
operative radiological surveillance11, which influences the
long-term cost-effectiveness of EVAR12.
Interest is therefore growing in developing prognostic
models to determine long-term results following EVAR,
which may lead to changes in the level of surveillance
required for some patients. A number of prognostic
variables measured either before or soon after surgery
have been shown to be associated with long-term free-
dom from aneurysm-related morbidity, including early
absence of endoleak, migration and kinking13,14, smaller
initial aneurysm diameter, younger age at operation15,
and morphological variables such as smaller maximum
common iliac diameter, aortic sac volume and maximum
sac diameter16. However, there has been relatively lit-
tle investigation of dynamic measures that change over
follow-up, such as the patient’s surveillance and surgical
history and, in particular, aspects of a patient’s aneurysm
sac diameter trajectory. The advantages of incorporating
dynamic measurements of secondary sac diameter history
into a prognostic model are twofold; first, they can be
used to update an individual’s risk prediction and hence
recommended time of next visit at each surveillance scan;
and, second, they can be measured accurately, cheaply and
safely throughout follow-up using ultrasonography.
The aim of this study was to develop and identify aspects
of sac diameter trajectory that predict future secondary
rupture or rupture-preventing reintervention (RPR) at
three distinct times during follow-up when reassessment of
an individual’s surveillance protocol may be necessary.
Methods
Data from the EVAR-1 and EVAR-2 trials2,17 were used
to develop a prognostic model for predicting secondary
rupture or RPR following EVAR. The trials implanted
EVAR devices between 1999 and 2004, which did not have
the advances of devices today, including imaging sizing
and improved techniques and technologies. Therefore, to
validate the risk predictions on a contemporary series, a
consecutive prospective cohort of patients who had elective
EVAR was recruited from Helsinki University Hospital
(HUH) in Finland.
The prognostic model was developed for risk prediction
purposes. The model was dynamic in nature and used a
landmarking approach18. Models were developed at three
preselected times after operation (2, 3 and 5 years), chosen
because there may be uncertainty at these times whether
patients should be invited back regularly, and for which a
prediction model could be used as a decision aid. At each
of these time points (landmark times), updated information
on the predicted current sac diameter and rate of sac
growth was incorporated into the prognostic model.
Data sets
The design and selection of participants in the EVAR-1 and
EVAR-2 trials have been described previously19. Briefly,
between 1 September 1999 and 3 August 2004, patients
aged over 60 years with an AAA of at least 5⋅5 cm and suit-
able for an operation were randomized to either EVAR or
open repair (EVAR-1 trial) or, if ineligible for open repair,
to EVAR versus no operation (EVAR-2 trial). For the pur-
poses of this study, only patients who underwent elective
EVAR were included. Patient follow-up was planned for
1month, 3months and 1 year after operation, and annu-
ally thereafter, comprising abdominal CT and recording of
any complications or adverse events. The management of
aneurysm-related complications was left to the discretion
of the trial centre. The present study used CT imaging data
that were recorded comprehensively between 1999 and
2009. Patients were followed up for reinterventions from
1 September 1999 to 1 September 2009 using local hospi-
tal records, and from 1 September 2009 to 31 March 2015
using predominantly record linkage to Hospital Episode
Statistics. Dates and causes of death were extracted using
record linkage from the Office of National Statistics from
1 September 1999 to 30 June 2015.
Validation data were obtained from HUH, which is
the only hospital providing vascular surgical services and
EVAR to 2⋅0 million inhabitants in Southern Finland. All
patients who underwent EVAR for intact elective infrarenal
AAA in HUH during 2000–2015 were included in the
present analysis. Basic demographics were extracted from
the hospital’s vascular registry. Data on the primary EVAR
procedure, possible aneurysm-related reinterventions and
imaging (digital subtraction angiography, CT, magnetic
resonance angiography (MRA) and ultrasound examina-
tions) during follow-up were collected retrospectively from
the case histories. CT images were reviewed for endoleaks,
migration and kinking, and sac diameter was measured if
not clearly stated in the radiological records. Dates and
causes of death were extracted from the hospital records
until the end of July 2017, and confirmed where possible
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with data from the Cause of Death registry of Statistics
Finland, which were available up to 31 December 2016. In
2000–2010, the surveillance protocol after EVAR included
CT at 1, 6 and 12months, and annually thereafter. How-
ever, if there were reinterventions or endoleaks, additional
CT was undertaken if considered necessary. After 2010,
the surveillance protocol was simplified to CT at 3 and
12months after the procedure, and annual ultrasonography
if no complications were detected (with a reference ultra-
sound examination at 6months). However, when there was
suspicion of a sac diameter increase from the ultrasound
images, CT (or MRA in selected patients if CT was con-
traindicated) was scheduled to determine the reason for sac
diameter increase and the need for reintervention.
Measurements and outcomes
The outcome investigated in this study was the time to
the next rupture or RPR after the three landmark times.
RPR events were included in the outcome as many rup-
tures could possibly have been prevented by early reinter-
vention. The aim was to develop a risk model that could
predict severe sequelae that would require immediate rein-
tervention. RPR was defined as any reintervention to pre-
vent sac growth and rupture. All candidate procedures were
reviewed and categorized as RPR or not. Reintervention
for a type II endoleak without sac expansion was not con-
sidered to be a RPR.
Statistical analysis
The TRIPOD guidelines20 for prediction model devel-
opment and validation were followed. A longitudinal
mixed-effects model was developed using EVAR trials
data on repeat measurements of sac diameter taken from
imaging scans. Fractional polynomial modelling21 was
used to select the best-fitting form for the trajectory
function over time. Individual variability around the mean
trajectory function was incorporated by including random
effects for the coefficients of the fractional polynomial.
Baseline characteristics were also investigated as possible
explanatory variables. Three separate models were fitted
using individuals still alive and under follow-up at 2, 3 and
5 years after operation; each incorporated all sac diameter
measurements up until the landmark time of interest. The
best linear unbiased predictors (BLUPs) of the random
effects were extracted to obtain the predicted sac diameter
and rate of growth for each individual at each landmark
time. For patients in the Helsinki cohort, BLUPs of the
random effects were derived based on the model coeffi-
cients estimated in the EVAR trials. Observed diameter
measurements in the Helsinki data were obtained from
a mixture of scan modalities. Non-CT measurements
(ultrasonography and MRA) were adjusted using the dif-
ference in the mean diameter between these modalities
and those on CT (estimates of which were obtained from
a mixed-effects model). Further details may be found in
Appendix S1 (supporting information).
A prognostic model was developed to predict the time to
next RPR or rupture following each landmark time, using
a Cox proportional hazards model. Risk factors considered
in the model included the predicted current aneurysm sac
diameter, the predicted rate of sac growth, the patients’
age at operation, sex, BMI, preoperative aneurysm diam-
eter, graft shape, smoking status, diabetes status, and the
number of previous complications detected and reinterven-
tions performed. Individuals without any longitudinal sac
measurements before the preselected landmark times were
dropped from the analyses when developing the prognos-
tic models. This study used a simple selection procedure
that avoided overfitting to obtain a parsimonious model22.
Risk factors that had at least one univariable P value smaller
than 0⋅010 across the three landmarkmodels were included
in a multivariable model. From this multivariable model
the following prognostic models were compared: M1, risk
factors in the multivariable model excluding predicted sac
diameter and rate of sac growth; M2, model M1 plus pre-
dicted sac diameter; M3, model M1 plus predicted rate of
growth; M4, model M1 plus predicted sac diameter and
rate of growth; M5, predicted rate of growth only. In addi-
tion, a further model (M6) considered only a crude rate of
sac growth as a predictor (calculated by taking the differ-
ence between the previous diameter measurement and the
preoperative diameter, and dividing by the time between
the measurements).
Risk scores were created at each landmark time and
were based on the linear predictor of the Cox model.
The predictive accuracy of the risk scores developed from
the EVAR trials was assessed by various methods: dis-
criminative ability was measured using C-indices, with
20-fold cross-validation for internal validation; the 2-year
predicted risk of rupture or requirement for RPR fol-
lowing the landmark time was calculated by combining
the risk score with the estimated baseline survivor func-
tion, and risk predictions were compared with observed
2-year risks via a calibration plot; and patients were clas-
sified as high or low risk based on a chosen cut-off point
of the 2-year predicted risk and compared with observed
event numbers in the 2 years following the landmark time.
The sensitivity and specificity of the risk classification
were obtained with patients who were censored during the
2 years excluded from the calculations. External validation
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of the risk scores was undertaken using data from the
Helsinki cohort.
Results
EVAR trials
Some 1656 patients were randomized in the EVAR trials
(1252 in EVAR-1 and 404 in EVAR-2). Patients who did
not undergo elective EVAR or whose operation was con-
verted to open repair during initial surgery (807 patients),
had no postoperative CT images or sac diameter mea-
surements available (60), or who underwent EVAR but
had a straight graft fitted (4) were excluded from the
analyses (Fig. S1a, supporting information). The remain-
ing 785 patients were available for analysis (Table 1). Of
these individuals, 700 (89⋅2 per cent) were men and the
mean age was 74⋅5 years. The mean preoperative maxi-
mum external AAA diameter was 6⋅49 (range 5–10⋅5) cm
and a mean of 5⋅4 CT scans per patient were acquired
over a mean follow-up of 4 years after operation (maximum
10 years). Mean follow-up for RPR or rupture was 7⋅1 years
(maximum 15⋅6 years).
During follow-up, 155 patients (19⋅7 per cent) had a
secondary rupture or RPR. There were 42 patients with at
least one secondary rupture and 138 with at least one RPR.
Twenty-five patients had both a rupture and RPR recorded
during follow-up. The rate of rupture remained relatively
stable across the landmark time points at approximately one
per 100 person-years, whereas the rate of RPR decreased
slightly over time from three per 100 person-years after
2 years to two per 100 person-years after 5 years.
Helsinki cohort
A total of 402 patients were studied in the Helsinki
cohort. After excluding 12 patients without any postop-
erative diameter measurements, 390 remained and were
used for external validation of the derived risk score (Fig.
S1b, supporting information). The patient characteristics
of the cohort were very similar to those in the EVAR-1
and EVAR-2 trials in terms of proportion of men (87⋅7
per cent), mean age (74⋅6 years), number of scans during
follow-up (mean 5⋅8) and duration of follow-up imaging
(mean 3⋅52 (range 0⋅003 to 14⋅2) years) (Table 1). The mean
preoperative AAA size was 6⋅30 cm, slightly smaller than
that in the EVAR trials. Postoperative aneurysm (sac) diam-
eters were measured using a mixture of CT (63⋅6 per cent),
ultrasound imaging (35⋅8 per cent) andMRA (0⋅6 per cent).
Seventy-three patients (18⋅7 per cent) experienced at
least one secondary sac rupture or RPR during follow-up.
Eleven patients had at least one secondary rupture and
66 underwent at least one RPR; four patients had both
a rupture and RPR recorded during follow-up. The rates
of secondary rupture were similar to those in the EVAR
trials at one per 100 person-years across the three landmark
times. However, the rate of RPRwasmore than double that
of the EVAR trials, ranging from a maximum of seven per
100 person-years after 3 years to five per 100 person-years
after 5 years. Although the proportions of patients who
underwent RPR during follow-up were similar in both
the EVAR trials and the Helsinki cohort, reinterventions
occurred sooner in the Helsinki cohort, at a mean of
2⋅8 years after operation compared with 3⋅7 years in the
EVAR trials.
Aneurysm sac trajectory modelling
The observed aneurysm sac trajectories of patients in the
EVAR trials and Helsinki cohort over a 10-year follow-up
interval were stratified by type of event (no rupture or
RPR, RPR with no subsequent rupture and secondary sac
rupture) (Fig. 1). Loess smoothers were added to the profile
plots to capture the average trajectory trends. In general,
the reduction in sac diameter occurred non-linearly over
follow-up, with a sharp decrease initially after operation,
before stabilizing. In patients in the EVAR trials who
underwent RPR during follow-up, the initial reduction in
sac diameter was less pronounced and the mean diameter
remained relatively high throughout follow-up. Patients in
the Helsinki cohort showed similar trajectories. In patients
whose aneurysm ruptured during follow-up, there was a
clear increase in the mean sac diameter over time for
patients both in the EVAR trials and Helsinki cohort.
However, the heterogeneity between patients was large,
with some who experienced AAA rupture still showing a
declining sac trajectory over time.
Longitudinal models were fitted to the EVAR data; func-
tions of time, patient age and preoperative AAA size were
statistically associated with postoperative sac diameters
(Table S1, supporting information). Mean trajectory func-
tions for each model fitted to data up to the three landmark
times are shown in Fig. S2 (supporting information).
Risk prediction of secondary sac rupture
and rupture-preventing reinterventions
The univariable associations between possible risk factors
and rupture or RPR in the EVAR trials are shown in Table
S2 (supporting information). Patients with a larger preop-
erative maximum aneurysm size had an increased risk of
RPR or rupture. The numbers of previous complications
and reinterventions were also significantly associated with
an increased risk of secondary rupture or RPR after EVAR.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 1294–1304
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Table 1 Patient characteristics in the EVAR trials and the Helsinki cohort
EVAR-1 and EVAR-2 trials Helsinki cohort
n No. of patients* n No. of patients*
Preoperative AAA size (cm)† 785 6⋅49(0⋅91) 390 6⋅30(0⋅90)
Age (years)† 785 74⋅5(6⋅4) 390 74⋅6(7⋅9)
Men 785 700 (89⋅2) 390 342 (87⋅7)
BMI (kg/m2)† 784 26⋅7(4⋅6) 390 27⋅3(5⋅3)
Diabetes 782 88 (11⋅3) 78 (20⋅0)
Smoking status 784
Current 159 (20⋅3) 98 (25⋅1)
Past 548 (69⋅9) –
Never 77 (9⋅8) –
Graft shape 765 389
Uni-iliac 57 (7⋅5) 7 (1⋅8)
Bi-iliac 708 (92⋅5) 382 (98⋅2)
No. of postoperative sac measurements† 785 5⋅4(2⋅7) 390 5⋅8(3⋅1)
Interval from operation to last follow-up imaging (years)† 785 4⋅03(2⋅51) 390 3⋅52(2⋅73)
Follow-up for RPR or rupture (years)† 785 7⋅1(4⋅1) 389 4⋅0(3⋅0)
Type of imaging used for sac diameter measurement 4230 2250
CT 4230 (100) 1430 (63⋅6)
Ultrasonography 0 (0) 806 (35⋅8)
Magnetic resonance angiography 0 (0) 14 (0⋅6)
No. of previous complications after surgery†
2 years 666 0⋅28(0⋅53) 287 0⋅74(1⋅33)
3 years 609 0⋅34(0⋅59) 226 0⋅96(1⋅72)
5 years 495 0⋅42(0⋅70) 121 1⋅10(2⋅00)
No. of previous reinterventions†
2 years 666 0⋅10(0⋅38) 287 0⋅19(0⋅52)
3 years 609 0⋅14(0⋅44) 226 0⋅32(0⋅76)
5 years 495 0⋅22(0⋅57) 121 0⋅47(0⋅91)
Predicted sac diameter after surgery (cm)†
2 years 659 5⋅85(1⋅31) 285 5⋅49(1⋅26)
3 years 607 5⋅77(1⋅50) 226 5⋅39(1⋅59)
5 years 495 5⋅66(1⋅69) 121 5⋅18(1⋅76)
Predicted rate of sac growth after surgery (cm/year)†
2 years 659 0⋅083(0⋅364) 285 0⋅041(0⋅364)
3 years 607 0⋅143(0⋅323) 226 0⋅101(0⋅336)
5 years 495 0⋅142(0⋅233) 121 0⋅114(0⋅255)
Secondary rupture or RPR 785 390
0 630 (80⋅3) 317 (81⋅3)
≥1 155 (19⋅7) 73 (18⋅7)
No. of deaths 785 615 (78⋅3) 389 163 (41⋅9)
Causes of death 615 163
Aneurysm-related after repair 13 (2⋅1) 2 (1⋅2)
Aneurysm rupture after repair (secondary) 33 (5⋅4) 7 (4⋅3)
Coronary heart disease 154 (25⋅0) 39 (23⋅9)
Stroke 37 (6⋅0) 9 (5⋅5)
Other vascular disease 23 (3⋅7) 12 (7⋅4)
Lung cancer 59 (9⋅6) 13 (8⋅0)
Other cancer 104 (16⋅9) 27 (16⋅6)
Respiratory 93 (15⋅1) 19 (11⋅7)
Renal 15 (2⋅4) 2 (1⋅2)
Other 81 (13⋅2) 17 (10⋅4)
Unknown 3 (0⋅5) 16 (9⋅8)
*With percentages in parentheses unless indicated otherwise; †values are mean(s.d.). AAA, abdominal aortic aneurysm; RPR, rupture-preventing
reintervention.
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Fig. 1 Trajectories of aneurysm sac diameter in the EVAR trials and Helsinki cohort over 10 years of follow-up, with loess smoothers
superimposed. Shaded areas represent 95 per cent confidence intervals. RPR, rupture-preventing reintervention
The number of previous complications was subdivided into
five types of complication to investigate the association of
each type with rupture or RPR separately. The occurrence
of migration and type I and II endoleaks during the study
interval was strongly associated with an increased risk
of rupture or RPR, and there was also a non-significant
positive association for type III endoleaks. There was
statistically significant evidence that both the current sac
diameter and the rate of sac growth increased the risk of
rupture or RPR.
Table 2 Multivariable hazard ratios from prognostic model M4 for risk of rupture or rupture-preventing reintervention at 2, 3 and
5 years after operation
2 years (n= 116 events) 3 years (n= 103 events) 5 years (n= 66 events)
n Hazard ratio P n Hazard ratio P n Hazard ratio P
Preoperative AAA size
(per cm)
659 1⋅94 (1⋅25, 3⋅02) 0⋅003 607 1⋅55 (0⋅98, 2⋅45) 0⋅062 495 1⋅09 (0⋅73, 1⋅63) 0⋅666
No. of previous
complications
659 1⋅76 (1⋅29, 2⋅42) <0⋅001 607 1⋅56 (1⋅15, 2⋅11) 0⋅004 495 1⋅16 (0⋅83, 1⋅62) 0⋅384
No. of previous
reinterventions
659 0⋅97 (0⋅65, 1⋅47) 0⋅899 607 1⋅28 (0⋅92, 1⋅80) 0⋅144 495 0⋅89 (0⋅56, 1⋅40) 0⋅613
Current sac diameter
(per cm)
659 0⋅68 (0⋅44, 1⋅05) 0⋅084 607 0⋅86 (0⋅54, 1⋅37) 0⋅532 495 1⋅21 (0⋅82, 1⋅78) 0⋅344
Current rate of sac
growth (per 2mm
per year)*
659 1⋅64 (1⋅31, 2⋅06) < 0⋅001 607 1⋅79 (1⋅25, 2⋅55) 0⋅001 495 1⋅80 (1⋅12, 2⋅89) 0⋅015
Values in parentheses are 95 per cent confidence intervals. *2mm/year is the standard deviation of the rate of sac growth. AAA, abdominal aortic
aneurysm. Hazard ratios were obtained by Cox proportional hazards analysis.
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Fig. 2 Predictive accuracy (C-index with 95 per cent c.i.) of six prognostic models (M1–M6) based on the EVAR trials and Helsinki
cohort. Model M1, preoperative abdominal aortic aneurysm size, previous numbers of complications and previous numbers of
reinterventions; model M2, model M1+ predicted sac diameter; model M3, model M1+ predicted rate of sac growth; model M4,
model M1+ predicted sac diameter+ predicted rate of growth; model M5, predicted rate of growth; model M6, crude rate of growth
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Table 3 Performance of prognostic model M5 incorporating predicted sac growth only in classifying patients as low or high risk based
on a risk score threshold
Landmark
time after
operation
2-year risk
threshold (%)
Approximate
threshold based on
growth rate
(mm/year)
Cases
classified
high risk*
Non-cases classified
low risk†
PPV: high-risk
patients who
are cases
NPV: low-risk
patients who
are non-cases
% classified
low risk
2 years
EVAR n= 47 n= 519
> 4 >–2 43 (91) 111 (21) 10 97 20
> 5 > –1 42 (89) 172 (33) 11 97 31
> 6 > 0 40 (85) 228 (44) 12 97 42
> 8 > 2 33 (70) 325 (63) 15 96 60
> 10 > 3 27 (57) 401 (77) 19 95 74
Helsinki n= 35 n=142
> 4 > –2 32 (91) 44 (31) 25 94 27
> 5 > –1 29 (83) 59 (42) 26 91 37
> 6 > 0 29 (83) 71 (50) 29 92 44
> 8 > 2 27 (77) 93 (65) 36 92 57
> 10 > 3 20 (57) 121 (85) 49 89 77
3 years
EVAR n= 45 n= 462
> 4 > 0 37 (82) 157 (34) 11 95 33
> 5 > 1 36 (80) 211 (46) 13 96 43
> 6 > 2 34 (76) 253 (55) 14 96 52
> 8 > 3 32 (71) 309 (67) 17 96 64
> 10 > 3 30 (67) 355 (77) 22 96 73
Helsinki n= 30 n= 108
> 4 > 0 28 (93) 53 (49) 34 96 40
> 5 > 1 27 (90) 62 (57) 37 95 47
> 6 > 2 25 (83) 69 (64) 39 93 54
> 8 > 3 23 (77) 77 (71) 43 92 61
> 10 > 3 20 (67) 90 (83) 53 90 69
5 years
EVAR n= 26 n= 378
> 4 > 1 22 (85) 209 (55) 12 98 53
> 5 > 2 20 (77) 246 (65) 13 98 62
> 6 > 2 18 (69) 274 (72) 15 97 70
> 8 > 3 14 (54) 315 (83) 18 96 81
> 10 > 4 12 (46) 334 (88) 21 96 86
Helsinki n= 12 n= 48
> 4 > 1 10 (83) 31 (65) 37 94 55
> 5 > 2 9 (75) 33 (69) 38 92 60
> 6 > 3 8 (67) 33 (69) 35 89 62
> 8 > 3 6 (50) 41 (85) 46 87 78
> 10 > 4 6 (50) 41 (85) 46 87 78
Values in parentheses are percentages (*sensitivity and †specificity). Cases are the patients who will have a ruptured aneurysm or rupture-preventing
reintervention during follow-up. PPV, positive predictive value; NPV, negative predictive value.
After adjusting for other predictors, only a few
co-variables remained significantly associated with the
risk of rupture or RPR. Table 2 shows the hazard ratios
(HRs) contributing to the full multivariable prediction
model (M4). Full regression coefficients and 2-year base-
line hazards for models M1–M6 at each of the three
landmark times are available in Table S3 (supporting infor-
mation). In particular, preoperative AAA size was still an
important predictor at 2 years, but its effect attenuated by
5 years after operation. Similarly, the number of previous
complications was associated with a higher risk at 2 and
3 years after surgery, but was not a significant predictor by
5 years. Current sac diameter was no longer an important
predictor once sac growth and preoperative AAA size had
been accounted for, whereas rate of sac growth remained
associated with an increased risk throughout follow-up.
At 2 years, the risk of rupture or RPR increased by 64 per
cent (HR 1⋅64, 95 per cent c.i. 1⋅31 to 2⋅06; P < 0⋅001)
for every 2-mm/year increase in the rate of sac growth.
For the same increase in rate of growth at 5 years, the
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risk increased by 80 per cent (HR 1⋅80, 1⋅12 to 2⋅89;
P = 0⋅015).
Calibration and predictive accuracy of the risk
scores
Two-year risk predictions from the full multivariablemodel
(model M4) were well calibrated with observed risks at all
three landmark time points in the EVAR trials data (Fig.
S3, supporting information). Predictive discrimination was
calculated for the six prognostic models (M1–M6). Fig. 2
shows the C-index value at 2, 3 and 5 years after operation
for patients in the EVAR trials and those in the Helsinki
cohort. The difference in C-index frommodelM1 is shown
in Fig. S4 (supporting information). At all landmark times
there was an improvement in the C-index when the rate
of growth was included in the model (model M3 versus
M1); the C-index values from the EVAR trials increased
from 0⋅64 to 0⋅70 at 2 years (difference 0⋅06, 95 per cent
c.i. 0⋅02 to 0⋅11; P= 0⋅004), from 0⋅66 to 0⋅74 at 3 years
(difference 0⋅08, 0⋅02 to 0⋅13; P= 0⋅006) and from 0⋅63 to
0⋅76 at 5 years (difference 0⋅13, 0⋅04 to 0⋅21; P= 0⋅003),
representing good discriminatory performance. Using rate
of growth alone as a predictor (model M5) also showed
good discriminatory performance, whereas using a crude
rate of growth performed poorly (model M6).
The prognostic models performed even better in the
external Helsinki cohort, with higher C-index values for
all landmark times and models. As with the EVAR trials,
there was an improvement in predictive accuracy, albeit
less pronounced, when rate of growth was included in the
models. There was an increase in C-index from 0⋅77 in
model M1 to 0⋅80 in model M3 at 2 years, and from 0⋅71
to 0⋅78 at 5 years.
Developing a classification rule
The performance of modelM5 (using predicted sac growth
alone) in correctly classifying individuals as high or low
risk was investigated. Patients in the EVAR trials and
Helsinki cohort were classified according to whether their
2-year risk prediction was greater or less than a thresh-
old value. Table 3 shows the estimated sensitivity, speci-
ficity, and positive and negative predictive values for various
2-year risk thresholds. Each 2-year risk threshold approx-
imates to an equivalent growth rate threshold. To ensure
high sensitivity (classifying the patients who will have an
aneurysm rupture or RPR (cases) that will occur in the
next 2 years as high risk), the threshold needs to be set
low (for example, considering a 2-year risk of more than
4–10 per cent as high risk). The results show that any
patient with a positive aneurysm growth rate (greater than
0mm/year) could be flagged as high risk at 2 or 3 years
after operation. This would identify more than 80 per cent
of all cases (in both the EVAR trials and the Helsinki
cohort), while enabling between 30 and 45 per cent of
all patients to be classified as low risk, with a potential
change in surveillance. At 5 years after operation, around
85 per cent of patients who have an RPR or aneurysm
rupture within the following 2 years have a growth rate
over 1mm/year. Using this as a threshold would allow over
50 per cent of patients to be classified as low risk at this
time point.
Discussion
A prognostic model was developed to predict secondary
rupture or RPR following EVAR for AAA. After control-
ling for other predictors, an increased risk was found to
be associated with larger preoperative AAA diameters, a
greater frequency of previous complications and higher
rates of sac growth. A longitudinal model that used a series
of repeat sac diameter measurements was used to obtain
a prediction of current sac growth that is less prone to
measurement error than a crude estimate of rate of growth
calculated using change from baseline (operation). The
rate of growth is an important predictor as it shows a
consistent association with risk throughout follow-up and
can be used to update individual risk to potentially enable
personalized surveillance.
The prognostic model based on changes in sac diam-
eter showed good predictive accuracy within the EVAR
trials and performed significantly better when the exter-
nal data set of patients who underwent EVAR in the
Helsinki region was used. This may be because there
was larger variation in patient characteristics (age, num-
ber of previous complications and reinterventions) in
the Helsinki cohort, which enables better discrimina-
tion of the population. Another possible explanation
could be improved imaging quality, leading to potentially
more accurate estimates of sac diameter and growth,
and better detection of underlying endoleaks leading to
reinterventions that are more closely aligned with sac
growth. With this knowledge, a centre would have greater
enthusiasm for annual follow-up with the expectation
of reducing the risk of rupture in an individual patient.
A third possible reason for better predictive accuracy in
the Helsinki data could be good adherence to patient
follow-up.
Although the model performed well on the external data,
there are several inconsistencies between the EVAR trials
and the Helsinki cohort. Data collection for the Helsinki
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region was mainly focused on five main complication cate-
gories: type I, II and III endoleaks, migration and kinking;
the EVAR trials registered additional complications such
as thrombosis and graft infection. The authors attempted
to standardize the definitions used across the two data sets,
and focused on the five categories referred to above. Sim-
ilarly, reinterventions were often coded differently in the
two data sets; a standardized coding of RPR was required
to harmonize the outcome. Use of the surrogate outcome
of rupture or RPR was chosen partly owing to small num-
bers of ruptures, which precluded the use of rupture as an
independent outcome in a prognostic model.
A risk score incorporating sac growth opens the door
to simple yet safe personalized surveillance. Sac diame-
ter can be measured reliably on an ultrasound device and
could potentially be measured in primary care, not requir-
ing a hospital visit. This would not only reduce costs, but
may also be more acceptable to the patient and keep more
patients in follow-up. Calculation of an individual’s pre-
dicted rate of AAA growth would need to be implemented
within a computer algorithm, although many risk calcula-
tors are now available onmobile phones23. A patient under-
going EVAR has a vested interest in ensuring that the sac
around the repair does not expand; if it does, more imaging
would be required to identify and correct the underlying
endoleak causing the sac diameter to increase. A safe and
acceptable lifelong follow-up schedule is therefore imper-
ative. More use of ultrasonography would dispense with
the need for annual exposure to radiation that occurs with
CT. The higher rates of cancer death late in follow-up after
EVAR in the EVAR-1 trial2 may have been related to the
reliance on follow-up by CT.
In EVAR-1, aneurysm-related mortality and all-cause
mortality were higher after 8 years in the EVAR group than
the open repair group2. The main cause of AAA-related
mortality was secondary sac rupture resulting from failure
to comply with annual imaging and reinterventions. It
follows that smarter surveillance protocols could reduce
not only mean costs but also rates of secondary sac
rupture and AAA-related mortality, thus improving the
cost-effectiveness of EVAR.
Future work should focus on the cost implications,
quality-of-life assessments and the cost-effectiveness of
various surveillance strategies after EVAR, including com-
paring how surveillance might be delivered (for example,
an annual close-to-home ultrasound sac diameter measure-
ment compared with a visit to secondary care for CT). It is
also important to study the efficacy of this predictive model
prospectively, to check the correlation between sac growth
and underlying correctable endoleak complication, kinking
or migration, and to investigate whether the correction of
these brings about a lower rate of secondary sac rupture and
improved survival.
A dynamic prognostic model incorporating secondary sac
growth has the potential to be used to tailor surveillance by
identifying a large proportion of patients who may require
less intensive follow-up as well as those who have a high
risk of secondary rupture or RPR within the next 2 years.
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